ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Launched by PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY · Apr 13, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called Ilumya, used alone or together with a skin ointment called Halog, for treating moderate-to-severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The trial is open to adult participants aged 18 and older who have been diagnosed with this condition and are suitable for other types of treatment, like phototherapy (light therapy) or systemic therapy (medications that affect the whole body).

To join the trial, participants must meet certain criteria, such as having a significant amount of skin affected by psoriasis. Women who can become pregnant need to have a negative pregnancy test and should use approved birth control methods during the study. Participants in the trial will receive either Ilumya or Ilumya with Halog and will be monitored for their response to the treatment. This trial is currently recruiting, so individuals interested in participating should check if they meet the eligibility requirements.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female adult ≥ 18 years of age;
• • 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
• • BSA 10%
• • PGA ≥3
• • PASI ≥12
• • 3. Must be a candidate for phototherapy and/or systemic therapy
• • 4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
• Exclusion Criteria:
• • 1. Non-plaque forms of psoriasis
• • 2. Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
• • 3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial.
• • 4. Active or untreated latent tuberculosis (TB)